TY - JOUR
T1 - ENDOCAN TUTHYREF network consensus recommendations
T2 - Anaplastic thyroid cancer
AU - Lamartina, Livia
AU - Jannin, Arnaud
AU - Decaussin-Petrucci, Myriam
AU - Bardet, Stéphane
AU - Escande, Alexandre
AU - Ciappuccini, Renaud
AU - Borson Chazot, Françoise
AU - Al Ghuzlan, Abir
AU - Do Cao, Christine
AU - Hadoux, Julien
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/7/1
Y1 - 2025/7/1
N2 - Anaplastic thyroid cancer is a rare and rapidly deadly disease. In case of clinical suspicion (rapid growth, stony neck mass), diagnostic work-up should be carried out as a matter of urgency to enable prompt treatment. Multidisciplinary assessment involving the patient's referring specialists, the support care team, and if necessary, a geriatric oncology specialist should be performed and must take account of disease extent, comorbidities, general health status and the patient's wishes. Patients and their families should receive realistic information about the prognosis; either active treatment in parallel to support care or exclusive palliative care can be recommended from the outset. Despite the dismal prognosis, recent advances in tumor molecular profiling and treatment with the advent of targeted treatment and immunotherapy hold out great promise for the future. This article summarizes the consensus recommendations on management of anaplastic thyroid cancers by the ENDOCAN TUTHYREF network, a rare-cancer network of the French National Institute for Cancer (INCa).
AB - Anaplastic thyroid cancer is a rare and rapidly deadly disease. In case of clinical suspicion (rapid growth, stony neck mass), diagnostic work-up should be carried out as a matter of urgency to enable prompt treatment. Multidisciplinary assessment involving the patient's referring specialists, the support care team, and if necessary, a geriatric oncology specialist should be performed and must take account of disease extent, comorbidities, general health status and the patient's wishes. Patients and their families should receive realistic information about the prognosis; either active treatment in parallel to support care or exclusive palliative care can be recommended from the outset. Despite the dismal prognosis, recent advances in tumor molecular profiling and treatment with the advent of targeted treatment and immunotherapy hold out great promise for the future. This article summarizes the consensus recommendations on management of anaplastic thyroid cancers by the ENDOCAN TUTHYREF network, a rare-cancer network of the French National Institute for Cancer (INCa).
KW - Immunotherapy
KW - Molecular biology
KW - Palliative care
KW - Refractory thyroid cancer
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=105005466113&partnerID=8YFLogxK
U2 - 10.1016/j.ando.2025.101788
DO - 10.1016/j.ando.2025.101788
M3 - Article
C2 - 40350149
AN - SCOPUS:105005466113
SN - 0003-4266
VL - 86
JO - Annales d'Endocrinologie
JF - Annales d'Endocrinologie
IS - 4
M1 - 101788
ER -